mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2

Kyeong Jin Kim, Li Qiang, Matthew S. Hayden, David P. Sparling, Nicole H. Purcell & Utpal B. Pajvani

Mechanistic target of rapamycin complex 1 (mTORC1), defined by the presence of Raptor, is an evolutionarily conserved and nutrient-sensitive regulator of cellular growth and other metabolic processes. To date, all known functions of Raptor involve its scaffolding mTOR kinase with substrate. Here we report that mTORC1-independent ('free') Raptor negatively regulates hepatic Akt activity and lipogenesis. Free Raptor levels in liver decline with age and in obesity; restoration of free Raptor levels reduces liver triglyceride content, through reduced β-TrCP-mediated degradation of the Akt phosphatase, PHLPP2. Commensurately, forced PHLPP2 expression ameliorates hepatic steatosis in diet-induced obese mice. These data suggest that the balance of free and mTORC1-associated Raptor governs hepatic lipid accumulation, and uncover the potentially therapeutic role of PHLPP2 activators in non-alcoholic fatty liver disease.
O besity-induced metabolic dysfunction manifests as multiple chronic medical conditions, including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). NAFLD contributes to the overall cardiovascular risk of obesity, but is also the most common chronic liver disease, predisposing to cirrhosis and hepatocellular carcinoma. Ageing and obesity are well-established risk factors for NAFLD, but the molecular mechanism underlying this risk is poorly defined, precluding specific pharmacologic strategies to target excess hepatic triglycerides.

The evolutionarily conserved mechanistic target of rapamycin (mTOR) is a phosphatidylinositol 3-kinase (PI3K)-like serine/threonine kinase that regulates cell growth in response to nutrient signals, as well as a recently discovered regulatory role in lipid homeostasis. Mice with liver-specific deletion of the mTOR complex 1 (mTORC1)-defining subunit Raptor (L-Raptor) show reduced SREBP (sterol regulatory element (SRE)-binding protein)-1c-dependent de novo (SRE)-regulated lipogenesis (DNL) and are thus protected from fatty liver. Inhibition of mTOR/Raptor interaction with the allosteric mTORC1 inhibitor rapamycin similarly blocks insulin-dependent SREBP1c activation in primary rat hepatocytes and liver. Consistently, SREs are highly enriched in promoters of rapamycin-sensitive genes, leading to the conclusion that mTORC1 is required for the lipogenic actions of insulin.

Surprisingly, mice with liver-specific deletion of Tsc1 (L-Tsc1), the endogenous inhibitor of mTORC1, are also spared from both age- and diet-induced hepatic steatosis. The molecular mechanism underlying this apparent contradictory result was discovered to be feedback inhibition preventing normal activation of the serine–threonine kinase Akt, which then interferes with SREBP1c function via modulation of Insig2a expression. Akt is a critical molecular node in insulin signal transduction to both gluconeogenic and lipogenic liver pathways. As such, mice lacking both hepatic Akt isoforms show marked defects in both insulin-mediated metabolic processes in liver—glucose intolerance, primarily but not exclusively due to loss of its inhibitory action on the gluconeogenic transcription factor FoxO1 (ref. 16), as well as a similar reduction in feeding-induced Srebp1c expression as mice lacking hepatic insulin receptor. Collectively, these results point to Akt activity as a key regulator of insulin action in liver, and suggest that it affects DNL via both mTORC1-dependent and -independent mechanisms.

Akt is primarily regulated by post-transcriptional means—insulin stimulation of PI3K induces membrane localization, unmasking Thr308 for phosphorylation by PDK1, which then triggers mTORC2 (mTOR complex 2)-mediated phosphorylation at Ser473 (refs 18,19). While the necessity for both Thr308/Ser473 phosphorylation events in physiologic Akt activation is well-established, mechanisms accounting for termination or negative regulation of Akt signalling are far less understood. Our lab has shown that altered mTORC1 complex stability is associated with increased Akt activity, although this phenotype may be attributed to circumvention of normal nutrient-regulated mechanisms of mTORC1 catalytic activity and feedback regulation of Akt, we hypothesized that mTORC1 stability has an additional, indirect role to terminate the Akt signal.

Herein we show that Raptor exists in both the mTORC1-bound and -independent (‘free’) state in liver of young, healthy mice, but that free Raptor levels decline markedly in ageing and obesity, coupled with increased Akt activity and hepatic triglyceride. Moderate hepatic Raptor overexpression to correct the free Raptor deficit reversed Akt hyperactivity, decreasing DNL and hepatic triglyceride accumulation by increasing protein stability of the recently identified Akt Ser473 phosphatase pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase 2 (PHLP2). Raptor overexpression prevents aging- or high-fat diet (HFD)-mediated reductions in PHLP2 levels, without adversely affecting either mTORC1/2 activity or whole-body glucose homeostasis. Consistently, mild hepatic PHLP2 overexpression reduced lipogenic gene expression and obesity-induced triglyceride accumulation, without affecting glucose tolerance. These data suggest an important modulatory action of the balance in free and mTORC1-bound Raptor in the bifurcation model of hepatic insulin action, as well as point to PHLP2 as a novel therapeutic target for NAFLD.

Results

Free Raptor levels decline in aged and obese liver. mTORC1 complexes are affected by hormonal signals and oxidative stress, likely through direct effects on mTORC1 subunits, and modulated by other upstream signals, such as IPMK and Notch. These data suggest that the mTOR/Raptor interaction is fluid. As liver-specific Raptor (L-Raptor) knockout mice show aging-dependent defects in ketogenesis and obesity-dependent reductions in lipogenesis, we hypothesized that mTORC1 component interaction may be altered in these pathophysiologic processes. We performed size-exclusion chromatography to fractionate detergent-free liver lysate from young mice, and in parallel, older or leptin-deficient (ob/ob) obese mice. In all three groups of mice, mTOR and GJL eluted in high-molecular weight (~800 kDa) fractions (Fig. 1a,b), consistent with mTORC1 complex dimer. Raptor was also found mostly in high-molecular weight fractions in older or obese mice, but livers from young mice showed a surprising amount of ‘free’ (~150 kDa) Raptor (Fig. 1a,b). We next sought confirmation of this finding using alternative biochemical methods. We exposed liver lysate to a cell-permeable, non-cleavable chemical cross-linker to trap native mTORC1 complexes, and again observed a marked decrease of free Raptor with aging or obesity, without change in other mTORC1/2 component distribution (Fig. 1c,d and Supplementary Fig. 1a–c). As total levels of mTOR and Raptor did not substantially change, we hypothesized that altered free Raptor reflected greater mTOR–Raptor association in aging or obesity. To test this, we exposed liver lysate to a cleavable cross-linker to ensure complete recovery of mTORC1 components. As predicted, whereas the interaction between mTOR and GJL was unchanged, mTOR–Raptor association was markedly increased in ob/ob mice (Supplementary Fig. 1d). Consistently, performing anti-mTOR immunoprecipitation using CHAPS detergent to sustain the mTOR–Raptor interaction in the absence of cross-linker, we found greater bound Raptor in ob/ob mice (Supplementary Fig. 1e).

Although the disappearance of free Raptor in the liver from aging or obese mice was consistent across multiple experimental platforms, we remained skeptical, as various in vitro manipulations have been shown to affect biochemical recovery of mTORC1 complexes without true impact on mTOR–Raptor binding. For instance, transient amino acid deprivation increases, while rapamycin treatment decreases immunoprecipitation efficiency of Raptor (Supplementary Fig. 1f), but neither stimulus altered free Raptor levels (Fig. 1e). This suggests that our observation of free Raptor in young liver is likely through a novel mechanism, and that nutrient and/or hormonal signals prompts a true change in Raptor–mTOR association. We investigated this possibility in vitro, to dissociate the various components of obesity and found that while transient/chronic hyperglycaemia or brief insulin exposure were ineffectual, prolonged high-dose insulin treatment to induce insulin resistance:
randomly.

further, we repeated the experiment in aged (12-month-old) or blocked by Ad-Raptor delivery (Fig. 2b). To push the hypothesis Raptor, aging-induced hepatic triglyceride accumulation was benefit in young mice, suggestive of a threshold effect of free Raptor levels (Supplementary Fig. 2a). While we observed no control, we transduced young mice, which have ‘normal’ free and increase free Raptor levels (Fig. 2a). As a further internal (Ad-GFP) to acutely increase the hepatic Raptor/mTOR ratio, (Ad-Raptor) or green fluorescent protein (GFP) control transduced adult mice with adenovirus encoding Raptor excessive triglyceride content, or hepatic steatosis. To test this, we induced metabolic dysfunction, which in liver manifests as beyond the above correlation, may be causative to aging/obesity-hypothesized that loss of free Raptor in the insulin-resistant state, Rescue of free Raptor levels prevents hepatic steatosis. We next hypothesized that loss of free Raptor in the insulin-resistant state, beyond the above correlation, may be causative to aging/obesity-induced metabolic dysfunction, which in liver manifests as excessive triglyceride content, or hepatic steatosis. To test this, we transduced adult mice with adenovirus encoding Raptor (Ad-Raptor) or green fluorescent protein (GFP) control (Ad-GFP) to acutely increase the hepatic Raptor/mTOR ratio, and increase free Raptor levels (Fig. 2a). As a further internal control, we transduced young mice, which have ‘normal’ free Raptor levels (Supplementary Fig. 2a). While we observed no benefit in young mice, suggestive of a threshold effect of free Raptor, aging-induced hepatic triglyceride accumulation was blocked by Ad-Raptor delivery (Fig. 2b). To push the hypothesis further, we repeated the experiment in aged (12-month-old) or diet-induced obese (DIO) mice, which have further elevations in hepatic triglyceride as compared with young or adult mice (Supplementary Fig. 2b). Remarkably, acute increase in free Raptor levels reduced liver triglyceride and liver weight in both aged (Fig. 2c and Supplementary Fig. 2c) and DIO mice (Fig. 2d and Supplementary Fig. 2d), proving that the observed free Raptor deficit in these states has biological consequence, as replacement can ameliorate aging/obesity-induced hepatic steatosis.

Given the known hepatocyte tropism of adenovirus, we hypothesized that free Raptor protects from steatosis through a cell–autonomous mechanism, consistent with unchanged body weight, adiposity and plasma fatty acids in Ad-Raptor mice (Supplementary Fig. 3a–c). Liver Acox and Cpt1a gene expression and plasma ketone levels were unchanged (Supplementary Fig. 3d,e), indicative of normal β-oxidation/ketogenesis. Plasma triglyceride was lower in Ad-Raptor mice (Fig. 2e), implying no increase in hepatic triglyceride secretion as very-low-density lipoprotein. Finally, to test DNL, we injected $^3$H$_2$O into Ad-Raptor and control mice, and measured incorporation of...
Figure 2 | Rescue of free Raptor prevents aging- and obesity-dependent hepatic steatosis. (a) Western blot from livers of adult Ad-GFP and Ad-Raptor male mice, following size-exclusion chromatography. Fractions 24 and 25 correspond to mTORC1-associated (~800 kDa) Raptor, while 34 and 35 to free (~150 kDa) Raptor. (b-d) Hepatic triglyceride (TG) in young or adult (n = 6/group) (b), aged (10- to 12-month-old) (n = 7/group) (c), or DIO (n = 5 per group) (d) Ad-GFP and Ad-Raptor male mice. (e-g) Plasma TG (e), hepatic fatty acid synthesis (f) and lipogenic gene expression (g) in young or adult, Ad-GFP and Ad-Raptor mice, killed after a 16 h fast followed by 4 h refeeding (n = 6 per group). *P<0.05, **P<0.01 as compared with the indicated control by two-way analysis of variance. All data are shown as the means ± s.e.m. All blots are representative of three independent experiments, and samples within each group chosen randomly.

Interestingly, we did find that phosphorylation of Akt at Ser473, another known mTORC2 substrate, was increased by aging in Ad-GFP, but not Ad-Raptor mice (Fig. 3a). PI3K/PDK1-mediated phosphorylation at Thr308 was unaffected (Fig. 3b), but we predicted that decreased Akt Ser473 phosphorylation in Ad-Raptor mice would be sufficient to reduce Akt kinase activity. Indeed, GSK3β Ser9 (Supplementary Fig. 5a) and general Akt substrate phosphorylation (Supplementary Fig. 5b) was lower, as was immunoprecipitated Akt kinase activity (Supplementary Fig. 5c). In addition, reduced Akt activity in Ad-Raptor livers led to a twofold increase in hepatic Insig2a expression (Supplementary Fig. 5c), supporting the conclusion that free Raptor regulates Srebp1c-mediated lipogenesis via an Akt-regulated but mTORC1-independent pathway.

Raptor increases PHLPP2 levels to terminate Akt signalling. Akt Ser473 phosphorylation was not altered in extra-hepatic tissues of Ad-Raptor mice (Supplementary Fig. 5d), suggesting a cell-autonomous effect of free Raptor on Akt activity, as opposed to a whole-body change in insulin sensitivity, consistent with normal plasma insulin levels (Supplementary Fig. 5e). These data prompted the hypothesis that Akt Ser473 dephosphorylation was increased in Ad-Raptor mice. PHLPPs, encoded by Phlpp1, with two splice variants (PHLPP1α and PHLPP1β), and Phlpp2, have recently been shown to dephosphorylate Akt Ser473 to terminate insulin/growth factor action. PHLPP1β and PHLPP2 are expressed in liver (Supplementary Fig. 6a), but Raptor overexpressionselectively increased PHLPP2 (Fig. 3d). PHLPP2 levels were unaffected by mTOR inhibitors (Fig. 3e) or increased mTORC1 activity in Tsc2

Free Raptor reduces Akt-mediated lipogenesis. We next investigated the molecular mechanism underlying free Raptor-mediated reduced lipogenesis. Data from rapamycin-treated hepatocytes and from L-Raptor mice has proven that mTORC1 activity is necessary for normal hepatic Srebp1c function. If Raptor overexpression reduces mTORC1 catalytic function in liver, similar to in vitro effects observed in HEK293 cells, we would expect impaired Srebp1c-dependent lipogenesis. Ad-Raptor-transduced liver, however, showed normal fasted or refed mTORC1 kinase activity on recombinant 4E-BP1, phosphorylation of canonical mTORC1 targets and hepatic protein content (Supplementary Fig. 4a-c), in stark contrast with the phenotype of L-Raptor mice. Consistently, mTORC1-dependent negative feedback on insulin signalling through IRS1 phosphorylation was unchanged (Supplementary Fig. 4d). We next tested an alternative hypothesis whereby the addition of excess Raptor could ‘steal’ shared mTOR components from mTORC2, and recapitulate the lower hepatic triglyceride observed in L-Rictor mice, but we observed normal mTOR interaction with Rictor and the shared mTORC1/2 component, GβL (Supplementary Fig. 4e). In addition, Ad-Raptor mice showed normal p-Akt Thr450 and PKCδ levels (Supplementary Fig. 4f,g), which are phosphorylated and stabilized by mTORC2 (refs 35,36).

label into newly synthesized hepatic fatty acid. We found that adult mice had higher rates of lipogenesis than young mice, but this was reversed by correcting the aging-related free Raptor defect (Fig. 2f). Consistently, we observed reduced expression of Srebp1c, the master regulator of lipogenesis, as well as its transcriptional targets in Ad-Raptor-transduced liver (Fig. 2g) and primary hepatocytes (Supplementary Fig. 3f).

mTOR interaction with Rictor and the shared mTORC1/2 component, GβL (Supplementary Fig. 4e). In addition, Ad-Raptor mice showed normal p-Akt Thr450 and PKCδ levels (Supplementary Fig. 4f,g), which are phosphorylated and stabilized by mTORC2 (refs 35,36).
knockout (Tsc2−/−) mouse embryonic fibroblasts (Supplementary Fig. 6c), but are markedly lower in livers of adult or HFD-fed L-Raptor mice (Supplementary Fig. 6d,e) and in shRaptor-transduced primary hepatocytes (Supplementary Fig. 6f). Conversely, acute mTOR knockdown to increase the Raptor/mTOR ratio, and thus free Raptor levels, increased

**Figure 3 | Free Raptor reduces Akt hyperactivity by stabilizing PHLPP2.** (a,b) Western blots from livers of young or adult Ad-GFP and Ad-Raptor mice killed after a 16 h fast followed by 4 h refeeding. (c) Akt activity on recombinant GSK3β peptide, normalized to immunoprecipitated Akt levels. (d) Western blot from liver of adult Ad-GFP and Ad-Raptor mice killed after a 16 h fast followed by 4 h refeeding, normalized to β-actin. (e) Western blot from Hepa1c1c7 cells treated with Rapamycin (20 nM) or Torin1 (250 nM). (f) Western blot from primary hepatocytes transduced with Ad-shControl or Ad-shmTOR. (g) Western blot of cycloheximide (CHX, 50 mg ml−1)-treated primary hepatocytes transduced with GFP or Raptor adenovirus. Quantification of PHLPP2, normalized to β-actin, relative to time 0 as 100%. (h,i) Western blot of Raptor (or GFP control)-transduced and/or HA/Ub-transfected primary hepatocytes following immunoprecipitation with anti-PHLPP2, with or without MG-132. *P<0.05 as compared with the indicated control by two-way analysis of variance. All blots are representative of three independent experiments, and samples within each group chosen randomly.
hepatocyte PHLPP2 (Fig. 3f). In summary, these data prove that free Raptor, but not mTORC1/2 activity, regulates PHLPP2.

Interestingly, Raptor overexpression did not increase Phlpp2 mRNA in liver or primary hepatocytes (Supplementary Fig. 6g,h), even as it induced protein levels of both basal and exogenous PHLPP2 (Supplementary Fig. 6i), suggesting an impact of free Raptor on PHLPP2 stability. Consistent with this hypothesis, Raptor overexpression maintained PHLPP2 levels in the face of cycloheximide treatment (Fig. 3g), likely due to reduced ubiquitin-mediated proteosomal degradation (Fig. 3h). β-TrCP (beta-transducin repeat-containing protein), the E3 ligase/substrate recognition subunit of the SCF (Skp1-Cullin 1-F-box protein) protein complex, has been shown to mediate PHLPP1 degradation in tumours—as this regulation is expected to be constitutively active Akt (Ad-myrAkt)39,40. We next performed the converse experiment, to test whether adenoviral rescue of PHLPP2 (Ad-PHLPP2) in DIO mice would inhibit hepatic lipid accumulation. As expected, Ad-PHLPP2 mice showed decreased Akt Ser473 phosphorylation (Fig. 4e). In addition, despite unchanged body weight and adiposity (Supplementary Fig. 7a), Ad-PHLPP2 mice showed increased liver weight and hepatic steatosis (Supplementary Fig. 7b,c), mirroring the phenotype of mice transduced with constitutively active Akt (Ad-myrAkt)39,40. Hepatic PHLPP2 levels decline with aging and in obesity. Free Raptor levels decline with aging and obesity—consistently, despite unchanged hepatic Phlpp2 gene expression (Fig. 4a), we observed lower PHLPP2 protein levels with aging and in dietary or genetic models of obesity (Fig. 4b–d). To test whether reduction in hepatic PHLPP2 is sufficient to induce steatosis, we constructed adenoviruses encoding shRNA targeting either Phlpp1 (Ad-shPHLPP1) or Phlpp2 (Ad-shPHLPP2). In primary hepatocytes, knockdown of PHLPP2 but not PHLPP1 increased Akt Ser473 phosphorylation (Supplementary Fig. 7a). Correspondingly, mice transduced with Ad-shPHLPP2 showed increased liver weight and hepatic steatosis (Supplementary Fig. 7b,c), mirroring the phenotype of mice transduced with constitutively active Akt (Ad-myrAkt)39,40. We next performed the converse experiment, to test whether adenoviral rescue of PHLPP2 (Ad-PHLPP2) in DIO mice would inhibit hepatic lipid accumulation. As expected, Ad-PHLPP2 mice showed decreased Akt Ser473 phosphorylation (Fig. 4e). In addition, despite unchanged body weight and adiposity (Supplementary Fig. 8a,b), Ad-PHLPP2 mice showed increased liver weight and hepatic steatosis (Supplementary Fig. 8c) and a trend towards lower hepatic triglyceride (Fig. 4f) and lipogenic gene expression (Fig. 4g), with an accompanying decrease in plasma triglyceride (Fig. 4h).

Figure 4 | Rescue of lower PHLPP2 in aging or obesity reduces lipogenesis. (a) Liver mRNA expression from young and adult mice (n = 6 per each group). (b–d) Western blot from livers of young and adult (b), chow- and HFD-fed (c), or lean and ob/ob (d) mice, normalized to β-actin. (e-h) Western blots from liver (e), hepatic triglyceride (f), liver lipogenic gene expression (g) and plasma lipids (h) in adult, HFD-fed Ad-GFP or Ad-PHLPP2 mice (n = 6–7/group). *P < 0.05, **P < 0.01 as compared with the indicated control by two-way analysis of variance. All data are shown as the means ± s.e.m.
These data suggest that preservation of free Raptor, via PHLPP2, can prevent hepatic steatosis, but to prove this, we co-transduced Ad-Raptor (or Ad-GFP control) mice with Ad-shControl, Ad-shPHLPP1 or Ad-shPHLPP2 adenoviruses. PHLPP2 knockdown restored Akt Ser473 phosphorylation in Ad-Raptor mice (Fig. 5a), resulting in hepatic and plasma triglyceride levels comparable to control mice (Fig. 5b,c), without altering body weight/adiposity or other serum metabolites (Supplementary Fig. 9a–d). PHLPP2 knockdown restored lipogenic gene expression (Fig. 5d), without affecting canonical mTORC1 signalling or activity (Supplementary Fig. 9e). Interestingly, Ad-myrAkt transduction in Ad-Raptor mice similarly increased liver triglyceride (Fig. 5e), buttressing our conclusion that free Raptor maintains normal hepatic lipogenesis/lipogenic gene expression, (Supplementary Fig. 9a–d). PHLPP2 knockdown restored glucose production.

Reduced hepatic Akt activity is typically associated with hyperglycaemia34. Surprisingly, but consistent with the phenotype of Ad-Raptor mice (Supplementary Fig. 10a–c), Ad-PHLPP2 mice showed normal glucose tolerance (Fig. 5f) and similar glucose and insulin levels as compared with control mice (Supplementary Fig. 10d,e). These data suggest that free Raptor, via PHLPP2, selectively regulates Akt’s effects on lipogenesis, while leaving intact Akt repression of hepatic glucose production.

Discussion

Although mTOR and Raptor expression tends to be tightly linked35, the association between these catalytic and primary scaffolding subunits of the mTORC1 complex is far more dynamic. Elegant biochemistry has shown that amino acid deprivation tightens, while rapamycin treatment loosens but does not break the mTOR–Raptor interaction24,32. While in vitro studies have hinted of the presence of an mTORC1-independent Raptor species27,42, our data proves for the first time the existence, and modulation by pathophysiologic (aging, obesity) stimuli, of free Raptor. Further study is required to determine whether free Raptor exists due to failure in association or true dissociation from mTOR, and whether the free and mTORC1-bound Raptor pools may interchange. In addition, what upstream signals (for example, alternative protein–protein interaction or a, post-translational modification on Raptor or another mTORC1 complex member) govern these event(s), and whether free Raptor affects other cellular processes are important questions that our lab is actively pursuing. Nevertheless, this first report of mTORC1-independent Raptor function suggests that its heretofore accepted role as a simple scaffold for mTOR catalytic activity is an oversimplification, and should prompt re-examination of the phenotypes of tissue-specific Raptor knockout mice.

Figure 5 | Reduced liver triglyceride (TG) by free Raptor is PHLPP2-dependent. (a–d) Western blots from liver (a), hepatic TG (b), plasma TG (c) and liver lipogenic gene expression (d) of adult Ad-GFP and Ad-Raptor mice co-transduced with control (Ad-shControl), Ad-shPHLPP1 or Ad-shPHLPP2 adenoviruses, killed after a 16 h fast followed by 4 h refeeding (n = 6 per group). (e) Hepatic TG from liver of adult Ad-GFP and Ad-Raptor mice co-transduced with control (GFP) or myrAkt adenovirus, killed after a 16 h fast followed by 4 h refeeding (n = 6 per group). (f) GTT in adult, HFD-fed Ad-GFP or Ad-PHLPP2 mice (n = 6–7 per group). *P < 0.05, **P < 0.01 as compared with the indicated control by two-way analysis of variance. All data are shown as the means ± s.e.m. All blots are representative of three independent experiments, and samples within each group chosen randomly.
The Raptor/PHLPP2 axis provides yet another mechanism of interplay, albeit indirect, between the insulin/Akt and nutrient/mTOR pathways. While there are likely additional determinants of hepatic PHLPP2, as evidenced by residual levels in L-Raptor livers, we postulate that insulin-Akt signalling, via free Raptor, may be responsible for its own regulation by PHLPP2. In fact, several predicted Akt and GSK3β phosphorylation sites exist in the C terminus of PHLPP2 within a β-TrCP-mediated destruction motif (phosphodegron), suggesting an Akt-dependent negative feedback loop to determine post-translational PHLPP2 stability to regulate Akt activity in obese liver. Conversely, a moderate free Raptor-induced increase in PHLPP2 levels can reduce Akt-regulated DNL via increased Ins2ga expression, but remarkably, does not impair glucose homeostasis. This is striking contrast to the phenotype of hepatic mTORC2-deficient (and thus Akt Ser473 phosphorylation-incompetent) L-Rictor mice, which fail to maximally activate Akt, leading to unchecked hepatic glucose output and glucose intolerance, closely approximating ‘complete’ hepatic insulin resistance. Integrating these data, we propose a new model of insulin action (Fig. 6) whereby Akt must be appropriately stimulated, but also inactivated by PHLPP2 in a timely fashion, to maintain normal hepatic physiology. Our model is consistent with the ‘bifurcation’ model of insulin signalling proposed by Brown & Goldstein, but differs in the kinetics of events— inhibition of FoxO1 to repress gluconeogenesis is an ‘early’ event and requires the full force of Akt action, but an extension of Akt activity by maintained Ser473 phosphorylation induces the ‘late’ lipogenic response to mTORC1-dependent and -independent pathways.

PHLPPs have been the subject of considerable research in recent years, due to their therapeutic potential in nonalcoholic disease. Loss-of-heterozygosity has been observed at both PHLPP loci in multiple solid tumours and a common PHLPP2 loss-of-function variant shown to reduce Akt dephosphorylation has been observed in high-grade breast cancers. In combination with the known oncogenic role of Akt, these findings suggest that PHLPPs may have tumour suppressor activity. Enthusiasm for pharmacologic PHLPP activators, such as HDAC3 inhibitors or adenylate cyclase activators, has been tempered by speculated interference with normal Akt function and potential to cause new-onset T2D, consistent with epidemiologic studies showing increased PHLPP1, but importantly not PHLPP2, expression in adipose or muscle of obese/T2D. Our, gain- and loss-of-function studies show that PHLPP1 has little function in liver, whereas hepatic PHLPP2 levels/activity dissociate Akt functions in liver to reduce lipogenesis without adversely affecting glucose tolerance. Our data would suggest that application of putative PHLPP2 agonists or liver-specific delivery of non-specific PHLP activators may have the potential to stem the tide of obesity-induced NAFLD.

Methods

Experimental animals. 8-week-old male wild-type C57/BL/6 mice fed on standard chow or HFD were purchased from Jackson Labs. We injected AAV8-TBG-GFP or AAV8-TBG-Cre (Penn Vector Core) into male Raptorlox/lox (Jackson Laboratory; stock number 013188) mice fed on standard chow or HFD, and characterized the mice at 2 weeks after AAV injection. Number of animals used in experiments was chosen to ensure adequate power to detect experimental difference with alpha set to 0.05. All animal experiments were conducted in accordance with guidelines of, and were explicitly approved by, the Columbia University Institutional Animal Care and Use Committee.

Metabolic analyses. Blood glucose (blood taken from tail vein) was measured using a glucometer (OneTouch) and plasma insulin concentrations were measured using a mouse insulin ELISA kit (Merodia). Glucose tolerance tests were performed by intraperitoneal injection of 2 g per kg body weight glucose after a 16 h fast. Hepatic lipids were extracted by the Folch method, and plasma and hepatic triglyceride, Cholesterol E and non-esterified fatty acid were measured using a colorimetric assay from Thermo or Wako Chemicals, according to the manufacturer’s protocol. We measured hepatic DNL by measuring the amount of newly synthesized fatty acid present in the liver 1 h after intraperitoneal injection of 1mCi of 3H2O.

Gel filtration chromatography and crosslinking assay. Liver tissues from three independent mice were pooled and lysed in hypotonic buffer (40 mM Tris-HCl (pH 7.5)) including protease inhibitors (Pierce) by repeated passage with a 27-gauge needle. The lysates were centrifuged at 14,000 r.p.m. for 15 min, and the supernatants were further centrifuged. The supernatant fraction was filtered through a 0.22-μm filter and was loaded onto a Superose 6 column (Amersham Biosciences) and eluted with 40 mM Tris-HCl (pH 7.5) and 150 mM NaCl.

Adenovirus studies. The GFP, Raptor and PHLPP1/2 adenoviruses have been described. The HA-Flag-PHLPP2 adenovirus was constructed by inserting a Flag sequence into HA-PHLPP2 vector (Addgene #22403, courtesy of Alexandra Newton) and adenoviruses encoding HA-Flag-PHLPP2 generated by Welgen, Inc. (Worcester, MA). Mouse shPhlpp1 or 2 target sequences were selected among three candidate sequences, respectively, and adenoviruses encoding shPhlpp1 or 2 generated by Welgen, Inc. Adenovirus expressing shmTOR, shRaptor and shRictor was generated by homologous recombination between pAd-Easy1 and pAd-Track vector. For in vivo studies, we injected 5 × 108 or 2.5 × 108 purified viral particles per gram body weight; we performed metabolic analysis on day 3–5 and sacrificed the mice at day 8 or 10 after injection. Infection with adenovirus in primary hepatocytes or Hepa1c1c7 cells was performed at 2.5, 5, or 10 multiplicity of infection.

Primary hepatocyte cultures. Primary mouse hepatocytes were isolated as previously described—in brief, mice were anesthetized with a ketamine/xylazine mixture (Sigma), abdominal cavity exposed and inferior vena cava catheterized with a 23-gauge catheter (Becton Dickinson). The superior vena cava was clamped, portal vein was transected and Hepes-based perfusion solution infused into the liver for 2 min at 5 cc min–1 followed by type I collagenase (Worthington Biochemicals), including protease inhibitor caplets (Boehringer Mannheim), for 18 min at the same flow rate. Liver cells were filtered, mixed with Percoll and spun at 1000 r.p.m. to remove dead cells and non-hepatocytes. After two washes, cells were plated at 0.8 × 106 cells per well of six-well dish in Williams E supplemented with 5% FCS (Invitrogen). For inhibitor experiments, we treated hepatocytes with 20 nM
rapamycin (Cell Signaling), 250 nM Torin1 or vehicle for either 1 or 24 h. The construct expressing HA/Ub was transfected using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s recommendation.

**Western blotting and co-immunoprecipitation.** Liver tissues or cells were lysed in a Triton-based or 0.3% CHAPS lysis buffer4 and whole-cell lysates were obtained by subsequent centrifugation. Immunoblots were conducted on 3–5 samples randomly chosen within each experimental cohort with antibodies against Raptor (#2280), Akt (#9272), p-Akt (S473, #4060), p-Akt (T308, #9275), p-Akt substrate (9614), PKCα (#2594), p-GSK3β (S9), p-GSK3β (S21), p-4E-BP1 (S653/S654/S655, #9459), p-4E-BP1 (S654/S655, #2855), p-GSK3α/β (#3205), p-IRS1 (S636/S639, #2388) and p-actin (#4970) from Cell Signaling; mTOR cell (sc-1549) and γ-tubulin (sc-12642) from SantaCruz Biotechnology, Inc.; PHLPP1 (A300-660A) and PHLPP2 (A300-661A) from Bethyl Laboratories, Inc; a polyclonal antibody against Raptor (#42-4000) from Invitrogen as well as protein A–HRP (10–023) from Pierce. Primary antibodies were used at 1:1,000 dilution. Uncropped images for all western blots can be found in Supplementary Fig. 11. For co-immunoprecipitation assays, liver extracts or cells were mixed with anti-mTOR or PHLPP2 antibody immobilized on Protein A or G-Sepharose (Invitrogen).

**Quantitative reverse transcription PCR.** We isolated RNA with TRIzol (Invitrogen) or the NEasy Mini kit (Qiagen), synthesized complementary DNA with High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) and performed quantitative reverse transcription PCR with a GoTaq SYBR Green qPCR Master Mix (Promega) in a CFX96 Real-Time PCR detection system (Bio-Rad). Primer sequences are available in Supplementary Table 1.

**In vitro mTORC1 or Akt kinase assay.** Liver lysates were immunoprecipitated with anti-mTOR or anti-Akt antibody (sepharose bead conjugated) and the immunoprecipitates were incubated with 4E-BP1 or GSK3 fusion protein substrate in kinase buffer for 30 min at 30°C. Reactions were terminated by SDS loading buffer. The samples were separated on SDS–PAGE, and the 4E-BP1 (T37/46) or GSK3β (S9) was detected by immunoblot.

**Statistical analysis.** We performed comparisons using two-way analysis of variance. All data are shown as the means ± s.e.m.

**References**

1. Ford, E. S., Giles, W. H. & Dietz, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey, JAMA 287, 356–359 (2002).
2. Li, S., Brown, M. S. & Goldstein, J. L. Insig-2, a second endoplasmic reticulum protein with element-binding properties. Proc. Natl Acad. Sci. USA 99, 12753–12758 (2002).
3. Li, S., Brown, M. S. & Goldstein, J. L. Activation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc. Natl Acad. Sci. USA 107, 3441–3446 (2010).
4. Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signaling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85–96 (2006).
5. Lu, M. et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18, 388–395 (2012).
6. Lin, H. V. & Accili, D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 14, 9–19 (2011).
7. Haas, J. T. et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 15, 873–884 (2012).
8. Stephens, L. et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279, 710–714 (1998).
9. Leslie, N. R., Biondi, R. M. & Alessi, D. R. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem. Rev. 101, 2365–2380 (2001).
10. Yuan, M., Pino, E., Wu, L., Kacergis, M. & Soukas, A. A. Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTORC) complex 2. J. Biol. Chem. 287, 29579–29588 (2012).
11. Haywortha, A. et al. Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c. Cell Metab. 15, 725–738 (2012).
12. Mora, A., Lipina, C., Tronche, F., Sutherland, C. & Alessi, D. R. Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem. J. 385, 639–648 (2004).
13. Pajvani, U. B. et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTORc1 stability. Nat. Med. 19, 1054–1060 (2013).
14. Kim, D. H. et al. mTORC1 interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110, 163–175 (2002).
15. Gao, T., Furnari, F. & Newton, A. C. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18, 13–24 (2002).
16. Brognard, J., Sirerici, E., Gao, T. & Newton, A. C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25, 917–931 (2007).
17. Menon, S. et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156, 771–785 (2014).
18. Kim, S. et al. Amino acid signaling to mTORC1 mediated by inositol polyphosphate multikinase. Cell Metab. 13, 213–221 (2011).
19. Sengupta, S., Peterson, T. R., Laplante, M., Oh, S. & Sabatini, D. M. mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468, 1100–1104 (2010).
20. Yip, C. K., Murata, K., Walz, T., Sabatini, D. M. & Kang, S. A. Structure of the human mTOR complex 1 and its implications for rapamycin inhibition. Mol. Cell 38, 768–774 (2010).
21. Jain, A. K. et al. Stoichiometry and assembly of mTORC1 complexes revealed by single-molecule pulldown. Proc. Natl Acad. Sci. USA 111, 17833–17838 (2014).
22. Kim, D. H. et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTORC1. Mol. Cell 11, 895–904 (2003).
23. Cook, J. R. et al. A mutant allele encoding DNA binding-deficient FoxO1 differentially regulates hepatic glucose and lipid metabolism. Diabetes 64, 1951–1965 (2015).
24. Wang, J. et al. Effects of adenosine-mediated liver-selective overexpression of protein tyrosine phosphatase-1b on insulin sensitivity in vivo. Diabetes Obes. Metab. 3, 367–380 (2001).
25. Facchini, V. et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27, 1932–1943 (2008).
26. Ikeneou, T., Inoki, K., Yang, Q., Zhou, X. & Guan, K. L. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27, 1919–1931 (2008).
27. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).
28. Li, X., Liu, J. & Gao, T. beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol. Cell Biol. 29, 6192–6205 (2009).
29. Calvisi, D. F. et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology 140, 1071–1083 (2011).
30. Li, L. et al. SCID Expression is dispensable for hepatic carcinogenesis induced by AKT and Ras oncogenes in mice. PLoS ONE 8, e75104 (2013).
31. Ono, H. et al. Hepatic Akt activation induces marked hypoglycemia, hepomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 52, 2905–2913 (2003).
32. Kaczka, T. et al. Tit1 and Tin2 are critical factors in mammalian target of rapamycin complex 2 regulation. J. Biol. Chem. 285, 20109–20116 (2010).
33. Michael, M. D. et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell 6, 87–97 (2000).

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10255 | www.nature.com/naturecommunications
44. Dong, X. C. et al. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. *Cell Metab.* 8, 65–76 (2008).

45. Haeusler, R. A. et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. *Nat. Commun.* 5, 5190 (2014).

46. Newton, A. C. & Trotman, L. C. Turning off AKT: PHLPP as a drug target. *Annu. Rev. Pharmacol. Toxicol.* 54, 537–558 (2014).

47. Brognard, J., Niederst, M., Reyes, G., Warfel, N. & Newton, A. C. Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. *J. Biol. Chem.* 284, 15215–15223 (2009).

48. Bradley, E. W., Carpio, L. R. & Westendorf, J. J. Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion. *J. Biol. Chem.* 288, 9572–9582 (2013).

49. Gao, M. H., Miyanohara, A., Feramisco, J. R. & Tang, T. Activation of PH-domain leucine-rich protein phosphatase 2 (PHLPP2) by agonist stimulation in cardiac myocytes expressing adenylyl cyclase type 6. *Biochem. Biophys. Res. Commun.* 384, 193–198 (2009).

50. Andreozzi, F. et al. Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese patients are associated with insulin resistance. *Diabetologia* 54, 1879–1887 (2011).

51. Cozzone, D. et al. Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients. *Diabetologia* 51, 512–521 (2008).

52. Mishra, N. et al. Efficient hepatic delivery of drugs: novel strategies and their significance. *Biomed. Res. Int.* 2013, 382184 (2013).

53. Folch, J., Lees, M. & Sloane Stanley, G. H. A simple method for the isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* 226, 497–509 (1957).

54. Zhang, Y. L. et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. *J. Biol. Chem.* 281, 37603–37615 (2006).

55. Miyamoto, S. et al. PHLPP-1 negatively regulates Akt activity and survival in the heart. *Circ. Res.* 107, 476–484 (2010).

56. Kim, K., Pyo, S. & Um, S. H. S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver. *Hepatology* 55, 1727–1737 (2012).

**Acknowledgements**

We thank A. Flete, J. Lee and T. Kolar for excellent technical support, and C. Eng as well as members of the Pajvani, Accili and Haeusler laboratories for insightful discussion. We also thank S.B. Lee for providing the HA/Ub plasmid. This work was supported by NIH DK093604 (U.B.P.), an Edward Mallinckrodt, Jr Foundation Grant (U.B.P.) and a Paul Marks Scholarship (U.B.P.).

**Author contributions**

U.B.P. conceived the project. K.K. and U.B.P. designed and performed the experiments, analysed the data and wrote the manuscript. L.Q., M.S.H., D.S. and N.H.P. performed the experiments.

**Additional information**

Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Kim, K. et al. mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2. *Nat. Commun.* 7:10255 doi: 10.1038/ncomms10255 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/